Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS [Yahoo! Finance]
Glaukos Corporation (GKOS)
Last glaukos corporation earnings: 2/27 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.glaukos.com/investors/investor-overview/default.aspx
Company Research
Source: Yahoo! Finance
Centers for Medicare and Medicaid Services (CMS). This prostaglandin analog is indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. The new J-code for iDose TR, J7355, is likely to become effective starting Jul 1, 2024. It is expected to increase patient access in the United States as it will likely accelerate the billing process and physician reimbursement. Price Performance In the past six months, GKOS's shares have rallied 34.7% compared with the industry's rise of 20.6%. The S&P 500 has gained 19.8% in the same time frame. Image Source: Zacks Investment Research More on the News iDose TR is a novel long-duration intracameral pharmacological therapy intended to continually provide therapeutic doses of a unique formulation of travoprost inside the eye for prolonged periods. By addressing the frequent patient non-compliance problems and persistent adverse effects connected to topical glaucoma drugs, iDose T
Show less
Read more
Impact Snapshot
Event Time:
GKOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GKOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GKOS alerts
High impacting Glaukos Corporation news events
Weekly update
A roundup of the hottest topics
GKOS
News
- Glaukos Co. (NYSE: GKOS) had its price target raised by analysts at BTIG Research from $107.00 to $112.00. They now have a "buy" rating on the stock.MarketBeat
- Glaukos Co. (NYSE: GKOS) had its price target raised by analysts at JPMorgan Chase & Co. from $108.00 to $110.00. They now have an "overweight" rating on the stock.MarketBeat
- Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y [Yahoo! Finance]Yahoo! Finance
- Glaukos Co. (NYSE: GKOS) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $125.00 price target on the stock, up previously from $120.00.MarketBeat
- Glaukos Co. (NYSE: GKOS) had its price target raised by analysts at Wells Fargo & Company from $103.00 to $110.00. They now have an "overweight" rating on the stock.MarketBeat
GKOS
Earnings
- 5/1/24 - Miss
GKOS
Sec Filings
- 5/1/24 - Form 8-K
- 4/16/24 - Form DEF
- 4/16/24 - Form ARS
- GKOS's page on the SEC website